The $800 Million Pill: The Truth Behind the Cost of New Drugs by Merrill Goozner (Paperback, 2005)
Brand newLOWEST PRICE
- AU $31.30Free postage
- Brand new condition
- Sold by simplybestprices-10to20dayshipping
- See details for delivery est.
- AU $23.95+ AU $7.95 postage
- Very good condition
- Sold by ausreseller
- See details for delivery est.
All listings for this product
About this product
- DescriptionWhy do life-saving prescription drugs cost so much? Drug companies insist that prices reflect the millions they invest in research and development. In this gripping expose, Merrill Goozner contends that American taxpayers are in fact footing the bill twice: once by supporting government-funded research and again by paying astromically high prices for prescription drugs. Goozner demonstrates that almost all the important new drugs of the past quarter-century actually originated from research at taxpayer-funded universities and at the National Institutes of Health. He reports that once the invative work is over, the pharmaceutical industry often steps in to reap the profit. Goozner shows how drug invation is driven by dedicated scientists intent on finding cures for diseases, t by pharmaceutical firms whose bottom line often takes precedence over the advance of medicine. A university biochemist who spent twenty years searching for a single blood protein that later became the best-selling biotech drug in the world, a government employee who discovered the causes for dozens of crippling genetic disorders, and the Department of Energy-funded research that made the Human Geme Project possible--these engrossing accounts illustrate how medical breakthroughs actually take place. The $800 Million Pill suggests ways that the government's role in testing new medicines could be expanded to eliminate the private sector waste driving up the cost of existing drugs. Pharmaceutical firms should be compelled to refocus their human and financial resources on true medical invation, Goozner insists. This book is essential reading for everyone concerned about the politically charged topics of drug pricing, Medicare coverage, national health care, and the role of pharmaceutical companies in developing countries.
- Author BiographyMerrill Goozner is former Chief Economics Correspondent at the Chicago Tribune. Winner of six Peter Lisagor Awards, Goozner is a contributing editor for The American Prospect. His work has also appeared in the New York Times, Washington Post, Boston Magazine, Columbia Journalism Review, Washington Monthly, Fortune Small Business, Slate.com, and Salon.com, among other publications.
- Author(s)Merrill Goozner
- PublisherUniversity of California Press
- Date of Publication29/09/2005
- SubjectMedicine: General
- Place of PublicationBerkerley
- Country of PublicationUnited States
- ImprintUniversity of California Press
- Weight454 g
- Width152 mm
- Height229 mm
- Spine22 mm
- Format DetailsTrade paperback (US)
Best-selling in Textbooks
- AU $190.23New
Marketing Management: an Asian Perspective by Swee Hoon Ang, Kevin Lane Keller, Siew-Meng Leong, Chin Tiong Tan, Philip Kotler (Paperback, 2013)
- AU $73.99New
- AU $61.14Used
- AU $93.21New
- AU $101.29New
- AU $70.76New
Save on Textbooks
- AU $69.90Trending at AU $81.85
- AU $22.10Trending at AU $23.82
- AU $87.99Trending at AU $90.37
- AU $73.99Trending at AU $78.30
- AU $39.15Trending at AU $50.15
- AU $69.89Trending at AU $73.99
- AU $104.88Trending at AU $108.61
This item doesn't belong on this page.
Thanks, we'll look into this.